10-Q/A: Solsence Restates Financials, Cites Internal Control Weaknesses

Solsence, Inc. has amended its Q2 2026 report to restate financial statements due to inventory costing errors, revealing material weaknesses in internal controls.

Summary

• Solsence, Inc. filed an amendment (10-Q/A) to its quarterly report for the period ended June 30, 2026, to restate previously issued financial statements.
• The restatement is due to errors in historical accounting for labor and overhead included in inventories, leading to overstated inventories and misstated cost of revenue.
• Material weaknesses were identified in inventory costing and in the oversight and review of financial reporting and restatement activities.
• As a result, the company's internal controls and disclosure controls and procedures were not effective as of June 30, 2026.
• Total revenue for the three months ended June 30, 2026, was $15.332 million, a decrease from $20.359 million in the same period of 2025.
• Total revenue for the six months ended June 30, 2026, was $28.290 million, a decrease from $34.984 million in the same period of 2025.
• A subsequent event notes a settlement agreement with Refy Beauty Ltd, resulting in a recognized settlement liability of $938,000 as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the restatement of financial statements, identification of material weaknesses in internal controls, and a decrease in revenue compared to the prior year period.

Positives

• The company is actively addressing accounting errors through restatements and implementing remediation plans for internal controls.
• Despite revenue decreases, cost of revenue also decreased, partly due to lower sales and improved production efficiency.
• Research and development expenses remained relatively flat, indicating continued investment in core technology.
• The company has a plan to remediate identified material weaknesses in inventory costing and financial reporting oversight.

Negatives

• The company was required to restate its interim consolidated financial statements for the period ended June 30, 2026, due to inventory costing errors.
• Material weaknesses were identified in inventory costing and oversight/review of financial reporting, rendering internal controls ineffective.
• Total revenue decreased by approximately 24.7% for the three months ended June 30, 2026, compared to the prior year period.
• Total revenue decreased by approximately 19.1% for the six months ended June 30, 2026, compared to the prior year period.
• Inventories, net, were overstated by $157,000 as of June 30, 2026, and by $3.632 million as of December 31, 2025, due to the restatement.
• Accumulated deficit increased by $156,000 as of June 30, 2026, and by $3.632 million as of December 31, 2025, due to the restatement.
• The company recognized a $938,000 settlement liability related to a dispute with Refy Beauty Ltd.

Risks

• The company's dependence on a limited number of key customers poses a risk, as a decision by one to cancel a purchase order or supply agreement could be detrimental.
• The company's loan agreements with Strandler, LLC and Beachcorp, LLC are set to expire on April 30, 2027, presenting an operating risk if they cannot be refinanced or extended.
• Potential for supplier price increases and wage/benefit inflation could materially affect operations and financial position if cost increases cannot be passed on to customers.
• The company faces risks related to the terms of its supply agreements with BASF, which could trigger a requirement to sell production equipment.
• Potential for new governmental regulations, particularly concerning nanomaterials, could be costly to comply with.
• The company's ability to remain consistently profitable despite past losses is a risk.
• Uncertain demand for and acceptance of its Solsence products and advanced materials.
• The company's limited marketing experience could impact its ability to grow sales.

Future Outlook

The company expects supplier price increases and wage/benefit inflation to potentially have a material effect on operations and financial position in 2026 and beyond, and will attempt to pass these costs to customers. Capital spending for 2026 is projected between $0.5 million and $1.5 million, funded by operations, existing credit lines, and potential new debt financing.

Management Comments

• Management has re-evaluated the effectiveness of internal controls over financial reporting as of June 30, 2026, and identified material weaknesses.
• Management concluded that the company's previously issued consolidated financial statements as of and for the years ended December 31, 2023, 2024, and 2025, and interim periods in 2024 and 2025, should no longer be relied upon.
• Management believes inflation has not had a material effect on operations or financial position for 2026, but expects future impacts.
• Management intends to implement remediation measures for inventory costing and financial reporting oversight.

Industry Context

StockSavvy.ai notes that the consumer health and beauty market, particularly in skin care and sun care, is highly competitive and driven by innovation in materials science and ingredient efficacy. The restatement and internal control issues at Solsence, while specific to the company, highlight the importance of robust financial reporting and operational controls in this sector, especially when dealing with proprietary technologies and FDA-regulated products.

Comparison to Industry Standards

• The restatement of financial statements due to inventory costing errors indicates a deviation from the expected standard of accurate financial reporting for publicly traded companies.
• The identification of material weaknesses in internal controls over financial reporting is a significant concern, as robust internal controls are a fundamental expectation for companies of this size and reporting status.
• The decrease in revenue for both the quarter and year-to-date periods compared to the prior year, while not uncommon in dynamic markets, warrants attention when coupled with the financial reporting issues.
• Competitors in the consumer health and beauty sector typically emphasize consistent revenue growth and profitability, alongside strong compliance and reporting standards.

Corporate Governance

Legal Proceedings

• Solsence, LLC entered into a Settlement Agreement and Release with Refy Beauty Ltd to resolve disputes relating to certain consumer care products. A settlement liability of $938,000 was recognized as of June 30, 2026.

Related Party Transactions

• The company has outstanding debt and lines of credit with related parties Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore.
• As of June 30, 2026, outstanding balances with Beachcorp, LLC were $13,287,000, and with Strandler, LLC were $1,000,000.
• Related party interest expense was $279,000 for the three months ended June 30, 2026, and $542,000 for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders: The restatement of financial statements and identified material weaknesses in internal controls can erode investor confidence and potentially impact share price.
• Creditors: The company's reliance on related party debt and the upcoming maturity dates of some loan agreements may be a concern for creditors.
• Suppliers: Potential for increased costs due to inflation could impact the company's ability to meet its obligations if these costs cannot be passed on.
• Customers: While not directly impacted by the restatement, the company's operational and financial stability is crucial for continued supply.

Next Steps

• Implement remediation measures for inventory costing methodologies and formalize policies.
• Evaluate and refine labor and manufacturing overhead cost pools, allocation practices, and assumptions.
• Strengthen documentation supporting burden rates, inventory valuation, and costing activities.
• Establish periodic reassessment requirements and comparisons of actual manufacturing costs with capitalized amounts.
• Enhance management review controls over inventory accounting and valuation.
• Strengthen technical cost-accounting and U.S. GAAP expertise through training, additional resources, and/or external specialists.
• Increase oversight by personnel with appropriate accounting and cost-accounting expertise.
• Enhance executive management oversight of significant accounting matters and review of third-party specialists.

Key Dates

Recommendation

The restatement of financial statements due to accounting errors, coupled with the identification of material weaknesses in internal controls, significantly undermines confidence in the company's financial reporting and operational integrity. The decline in revenue and shift to net losses further exacerbate these concerns. Until these issues are fully remediated and a track record of consistent financial performance is re-established, a cautious approach is warranted.

Keywords

inventory costing, financial restatement, internal controls, material weakness, consumer health, beauty products, personal care ingredients, advanced materials